InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer

Oppenheimer initiated coverage on shares of InflaRx (NASDAQ:IFRX) in a report issued on Friday. The brokerage set an “outperform” rating and a $5.00 price target on the stock. Oppenheimer’s price objective points to a potential upside of 237.84% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of InflaRx in a research report on Tuesday, December 30th. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st. Guggenheim reiterated a “buy” rating and set a $14.00 price objective on shares of InflaRx in a research note on Tuesday, April 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research note on Friday, March 27th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, InflaRx currently has an average rating of “Moderate Buy” and a consensus price target of $6.50.

InflaRx Stock Down 5.1%

NASDAQ IFRX opened at $1.48 on Friday. InflaRx has a twelve month low of $0.71 and a twelve month high of $1.94. The stock has a market cap of $106.99 million, a P/E ratio of -1.95 and a beta of 1.49. The company’s 50-day simple moving average is $1.02 and its 200 day simple moving average is $1.10.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings results on Friday, March 20th. The company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). The business had revenue of ($0.04) million for the quarter, compared to the consensus estimate of $0.03 million. Research analysts anticipate that InflaRx will post -0.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of IFRX. Bank of America Corp DE bought a new stake in InflaRx during the 3rd quarter worth approximately $3,316,000. Suvretta Capital Management LLC raised its position in InflaRx by 22.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after purchasing an additional 1,450,000 shares during the last quarter. 683 Capital Management LLC raised its position in InflaRx by 47.3% in the 4th quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after purchasing an additional 1,065,000 shares during the last quarter. Woodline Partners LP acquired a new position in InflaRx in the first quarter worth $766,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in InflaRx in the second quarter worth $262,000. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.